Medication info
Olmesartan Medoxomil and Amlodipine Tablets 10/40mg (Olmesartan Medoxomil, Amlodipine Besylate)

Olmesartan Medoxomil and Amlodipine Tablets 10/40mg (Olmesartan Medoxomil, Amlodipine Besylate)

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›13.888mg / 1 tablet
Manufacturer / importer
Unimed Pharmaceutical Co., Ltd.
Appearance
Brownish-red round film-coated tablets
Packaging
28 tablets/PTP
Approval status
Active

MFDS item code 201406137 · Approved 2014.12.30 · Insurance code 649508500

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced intravascular effective circulating volume: In patients who may have reduced intravascular effective circulating volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring the patient’s condition. ∘Patients with hepatic impairment: Use caution when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
The safety and efficacy of this medicine in pediatric patients younger than 18 years have not been established.

Ingredients

Manufacturer
Unimed Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not well controlled with monotherapy using Amlodipine or Olmesartan Medoxomil. It effectively lowers blood pressure and helps reduce the risk of cardiovascular complications. This medication contributes to blood pressure control by dilating blood vessels and facilitating blood flow. Therefore, consistent use in hypertension treatment can help improve heart health. This medication is useful for patients struggling to control their blood pressure.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced intravascular effective circulating volume: In patients who may have reduced intravascular effective circulating volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring the patient’s condition. ∘Patients with hepatic impairment: Use caution when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

The safety and efficacy of this medicine in pediatric patients younger than 18 years have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; thus, it should be discontinued immediately upon confirmation of pregnancy. It should not be used by patients who are allergic to this drug's main components or similar medications, pregnant or nursing women, patients with severe liver disease or certain heart conditions, and patients undergoing kidney dialysis. Patients with a deficiency of body fluids or electrolytes should take this medication with caution at the beginning of treatment, as their blood pressure may drop too low. They should seek appropriate treatment immediately if symptoms appear. Patients with severe heart disease, congestive heart failure, or impaired kidney function should use this medication carefully. Side effects such as dizziness, headache, hypotension, swelling, dyspepsia, and others may occur while taking this medication, and any adverse reactions should be reported to a physician immediately. Unlike beta-blockers, this medication should not be discontinued abruptly, and there may be drug interactions when taken with other medications; therefore, consultation with healthcare providers is essential. It is generally advisable not to use this medication during pregnancy, and if planning for pregnancy, switching to safer alternative medications that have been confirmed for safety is recommended. Nursing mothers should consider discontinuing breastfeeding or the medication because it may pass into breast milk. Children under 18 years old should not use this medication, as its safety and efficacy have not been established. Elderly patients may have decreased kidney and liver function; thus, careful monitoring and dosage adjustment are required when taking this medication. In case of overdose, blood pressure may drop excessively, and heart rates may increase, necessitating immediate medical treatment and careful monitoring of blood pressure and heart function. This medication should be kept out of reach of children and stored in a tightly sealed container away from moisture, heat, and direct sunlight; transferring it to another container should be avoided.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory impairment, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, indigestion, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, low back pain, frequency of urination, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, weakness, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transpeptidase, decreased hemoglobin and hematocrit, low back pain, bronchitis, increased creatine phosphokinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, weakness, angioedema, chronic malabsorption-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, hair loss, itching, autoimmune hepatitis, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, marked peripheral vasodilation, hypotension, tachycardia, non-cardiogenic pulmonary edema, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is also safe to store at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Brownish-red round film-coated tablets

Package unit

28 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.